Treatment of patients with AL amyloidosis with high-dose melphalan and autologous peripheral blood stem cells (PBSC) produces hematologic remissions in approximately 40% of evaluable patients, accompanied by improvements in organ disease and quality of life. These patients, who frequently have amyloid deposits in bone marrow blood vessels and interstitium and impaired function of kidneys, liver, spleen, and heart, represent an unusual population for stem cell transplantation, with unique problems. To identify factors influencing engraftment rates after chemotherapy and autologous granulocyte colony-stimulating factor (G-CSF)-mobilized PBSC reinfusion, we studied a group of 225 patients. The median time to neutrophil engraftment was 10 days (range, 8-17 days). In a multivariate analysis, the factors positively affecting the rate of neutrophil engraftment were CD34 þ stem cell dose, female gender, and minimal prior alkylator therapy. The median time to platelet engraftment was 13 days (range, 7-52 days). Factors positively affecting platelet engraftment, in addition to CD34 þ cell dose, included preserved renal function and the absence of neutropenic fever. The conditioning dose of intravenous melphalan was not found to be an independent predictive factor for hematopoietic recovery. Thus, in this patient population, organ function and host and hematopoietic factors influence engraftment after PBSC rescue. Bone Marrow Transplantation (2005) 35, 567-575.
Summary:
Treatment of patients with AL amyloidosis with high-dose melphalan and autologous peripheral blood stem cells (PBSC) produces hematologic remissions in approximately 40% of evaluable patients, accompanied by improvements in organ disease and quality of life. These patients, who frequently have amyloid deposits in bone marrow blood vessels and interstitium and impaired function of kidneys, liver, spleen, and heart, represent an unusual population for stem cell transplantation, with unique problems. To identify factors influencing engraftment rates after chemotherapy and autologous granulocyte colony-stimulating factor (G-CSF)-mobilized PBSC reinfusion, we studied a group of 225 patients. The median time to neutrophil engraftment was 10 days (range, 8-17 days) . In a multivariate analysis, the factors positively affecting the rate of neutrophil engraftment were CD34 þ stem cell dose, female gender, and minimal prior alkylator therapy. The median time to platelet engraftment was 13 days (range, 7-52 days). Factors positively affecting platelet engraftment, in addition to CD34 þ cell dose, included preserved renal function and the absence of neutropenic fever. The conditioning dose of intravenous melphalan was not found to be an independent predictive factor for hematopoietic recovery. Thus, in this patient population, organ function and host and hematopoietic factors influence engraftment after PBSC rescue. Bone Marrow Transplantation (2005) 35, 567-575. doi:10.1038/sj.bmt.1704826 Published online 24 January 2005 Keywords: AL amyloidosis; stem cell transplantation; engraftment Autologous bone marrow transplantation was developed as a technique to rescue hematopoiesis after high-dose chemotherapy. In recent years, stem cells collected by leukapheresis from peripheral blood after the administration of myelosuppressive chemotherapy or myeloid growth factors has largely replaced bone marrow as the source of stem cells. This offers not only a less invasive and more economical method of collecting stem cells, but PBSCs produce more rapid hematopoietic engraftment, reducing the period of neutropenia and thrombocytopenia and decreasing the risks of life-threatening infection and bleeding. [1] [2] Several studies have shown an association between the CD34 þ cell dose administered and the rate of hematopoietic engraftment after high-dose chemotherapy in patients with hematologic malignancies. 3, 4 We and others have employed high-dose melphalan chemotherapy and autologous stem cell transplantation (HDM/SCT) for the treatment of AL amyloidosis. 5, 6 AL amyloidosis is a clonal plasma cell disorder in which extracellular fibrillar amyloid protein deposits composed primarily of immunoglobulin light chains accumulate in tissues. [7] [8] [9] Although some patients can present with AL amyloidosis and multiple myeloma, in most AL amyloidosis patients, the burden of clonal plasma cells in the bone marrow is comparatively low and diagnostic criteria of myeloma are usually absent. Unlike in myeloma, AL amyloidosis patients typically present with cardiac, renal, hepatic, gastrointestinal and/or neuropathic disease due to accumulation of amyloid fibrils. In addition, there is frequently evidence of amyloid deposits in the microvasculature or interstitium of the bone marrow. 10 Here, we examined the impact of these factors upon hematopoietic engraftment in a retrospective analysis of 225 AL amyloidosis patients who underwent treatment with HDM/SCT.
Patients and methods

Study population
Patients with a diagnosis of AL amyloidosis in the absence of multiple myeloma who were evaluated at our institution between August 1994 and July 2002 were considered in this study. Patients were excluded if they had undergone a bone marrow stem cell collection or were mobilized with a regimen other than G-CSF alone. Therefore, this study population includes most but not all of the study population of patients treated with high-dose melphalan and peripheral blood or bone marrow stem cell rescue for which the clinical outcome was recently reported. 5 All patients had biopsy-proven amyloid disease and a plasma cell dyscrasia, defined as clonal plasma cells in the bone marrow, and/or monoclonal gammopathy in serum or urine detected by immunofixation electrophoresis. For patients who underwent a second cycle of melphalan chemotherapy and stem cell transplantation, only the information from the first cycle was included in the analysis. All patients gave informed consent for data collection and treatment on protocols approved by the Institutional Review Board of Boston University Medical Center.
Mobilization procedure, PBSC harvest, and reinfusion
Hematopoietic progenitor cells were mobilized by subcutaneous administration of G-CSF at a dose of 16 mg/kg/ day for 3 days preceding leukapheresis. On each day of leukapheresis, an aliquot of the collected cells was subjected to flow cytometry to determine the number of CD34 þ progenitor cells, and the remainder of the leukapheresis product was cryopreserved at a cell concentration of 4 Â 10 8 mononuclear cells/ml in 10% DMSO and 20% autologous plasma. The cells were frozen at À801C for 24 h, and then moved to À1801C in the vapor phase of liquid nitrogen.
The dose of intravenous melphalan administered was determined by the particular treatment protocol, and ranged from 100 to 200 mg/m 2 melphalan divided over 2 days. At 24-72 h after the last dose of chemotherapy, the cryopreserved stem cells were thawed at the bedside and reinfused via an indwelling central venous catheter. The day of stem cell infusion was designated as day 0. All patients received G-CSF at a dose of 5 m/kg, which started on day þ 1 and continued until neutrophil engraftment. Patients also received erythropoietin (EPO) at a dose of 100 U/kg three times weekly. Red blood cell (RBC) and platelet transfusions were administered to maintain a hematocrit greater than 25% and a platelet count greater than 10 Â 10 9 /l, or higher if clinically indicated.
Statistical analysis
The primary outcome examined was days to hematopoietic engraftment. Neutrophil and platelet engraftment were analyzed separately and were defined by a neutrophil count X0.5 Â 10 9 /l and an untransfused platelet count X20 Â 10 9 /l, respectively. A secondary outcome was the median number of RBC units transfused during the treatment period. LOESS (locally weighted regression) was used to examine the relationship between stem cell dose and mean time to engraftment and RBC transfusion requirements. 11 We fit a weighted linear regression of the outcome at any value of a predictor variable, taking the 50% of the data closest to each predictor value.
Kaplan-Meier estimator analyses were performed for actuarial probabilities of neutrophil and platelet engraftment. Patients who died or who were lost to follow-up prior to engraftment were censored on the date of death or last day of contact. The log-rank test was used to summarize the time to engraftment by covariates: CD34 þ cell dose infused, gender, age, performance status according to Southwest Oncology Group (SWOG), cytomegalovirus (CMV) status, bone marrow involvement by amyloidosis, proteinuria, serum creatinine level, intravenous melphalan dose during transplantation, cumulative dose of oral melphalan prior to transplantation, and time interval between the last day of melphalan infusion and day 0. Time to platelet engraftment was also analyzed by the presence of neutropenic fever during the transplant period. In the analysis of covariates, the CD34 þ stem cell dose was categorized with a series of discrete cutoffs to identify the doses giving the greatest discrimination for the end points of neutrophil and platelet engraftment. Bone marrow involvement was divided into four histopathological categories: 0, no amyloid deposits; 1, amyloid in the microvasculature; 2, amyloid in the interstitium; and 3, extensive interstitial deposits. 10 Serum creatinine level was categorized as p1.20 , 1.21-2.00, or 42.00 mg/dl. Proteinuria was categorized as o5 g/day or X5 g/day. The cumulative dose of oral melphalan prior to transplantation was categorized as 0-100 or 4100 mg.
Cox proportional hazard regression models were used to analyze hazard ratios (HR) for time to engraftment by covariates in both univariate and multivariate analyses. Multivariable regression models were fitted in which all covariates previously selected as having prognostic value at the 10% level were introduced simultaneously with the CD34 þ stem cell dose. Final models were presented by regression parameter estimates and graphically using covariate-adjusted engraftment curves. Multiple linear regression analysis was performed to examine the association between RBC transfusions and the predictors including baseline variables and transplant-related variables as neutropenic fever and grade 3-4 (serious or life-threatening) hemorrhage. All statistical tests were two-sided; a significance level of Pp0.05 was chosen. Statistical analyses were performed with SPSS, version 9.0.1.
Results
Patients
A total of 225 patients who underwent PBSC mobilization with G-CSF followed by treatment with HDM/SCT were eligible for analysis. An additional 35 patients who began mobilization with G-CSF were excluded from the study population because they did not proceed to HDM/SCT; 10 patients died during G-CSF mobilization or stem cell collection and 25 patients did not complete collection due to complications including hypotension, hypoxemia, gastrointestinal bleeding, or a decline in performance status. Baseline clinical and laboratory characteristics of the study patients are shown in Table 1 . The median age of the patients was 57 years (range, 29-80) and the ratio of male to female patients was 1.5:1.0. The median dose of CD34 In the post transplantation setting, 126 patients (56%) developed neutropenic fever, and 11 of these had clinical features consistent with sepsis. In all, 31 patients (13.8%) had grades 3-4 hemorrhage. A total of 13 patients in this cohort of AL amyloidosis patients who underwent HDM/SCT (6%) died within 100 days of transplantation.
Hematopoietic engraftment
LOESS curves were generated to analyze the relationship between stem cell dose and time to neutrophil engraftment ( Figure 1a ), platelet engraftment (Figure 1b) , and RBC transfusion requirement (Figure 1c ). These suggested that there was a negative relationship, as expected, and Cox a One marrow involvement was graded as follows: 0 ¼ absent; 1+ ¼ blood vessels only; 2+ ¼ blood vessels and focal interstitial deposition of 2 or fewer high-power fields; or 3+ ¼ prominent interstitial deposition of more than two high-power fields. 10 regression analyses using varying stem cell doses as discrete cutoffs demonstrated that a dose of 3.0 Â 10 6 CD34 þ cells/ kg gave the greatest discrimination for the end points of neutrophil and platelet engraftment. Consistent with the concave shape of the LOESS curve (Figure 1c 
Neutrophil engraftment
A total of 221 patients achieved neutrophil engraftment (98.2%); four patients who died during the first 19 days after transplantation without neutrophil engraftment were censored. The median time to engraftment was 10 days (range 8-17 days). The median time to neutrophil engraftment of patients who received 43.0 Â 10 6 CD34 þ cells/kg was 10 days (25th and 75th percentiles, 9 and 11 days). For patients who received o3.0 Â 10 6 CD34 þ cells/kg, median neutrophil engraftment occurred at 11 days (25th and 75th percentiles, 10 and 12 days) ( Table 2) .
A Cox proportional hazard regression model showed that female gender, prior melphalan dose p100 mg, and CD34 þ cell dose 43.0 Â 10 6 /kg were associated with rapid engraftment in univariate and multivariate analyses (Tables 1 and 3, Figure 2 ). In the multivariate analysis, expressed as a hazard ratio for engraftment at any time, the rate of neutrophil engraftment was 1.55 times higher for patients who received 43.0 Â 10 6 /kg CD34 þ cells than for patients who received a lower dose (95% CI 1.10-2.19, P ¼ 0.01). Patients who received 45 Â 10 6 /kg CD34 þ cells had a rate of neutrophil engraftment that was 1.4 times higher than for patients who received 3.1-5.0 Â 10 6 CD34 þ /kg (95% CI ¼ 1.02-1.91, P ¼ 0.04). However, for patients who received 45 Â 10 6 /kg CD34 þ cells, there were no differences in the rate of neutrophil engraftment with further increases in stem cell dose. Female patients had 1.51 the rate of neutrophil engraftment of males (95% CI 1.14-2.00, Po0.01). Patients who had received o100 mg of oral melphalan prior to transplantation had 1.53 times the rate of neutrophil engraftment compared to those who had received 4100 mg (95% CI 1.04-2.26, P ¼ 0.03).
The interval between chemotherapy and stem cell reinfusion did not affect the rate of neutrophil engraftment, as measured from day 0 of stem cell reinfusion (Table 1) . Given this result, as would be expected, the duration of neutropenia was longer when reinfusion was delayed. The median number of days of neutropenia were 4 days with a 24 h delay, 5 days with a 48 h delay, and 6 days with a 72 h delay.
Platelet engraftment
A total of 212 patients (94.2%) achieved platelet engraftment; 13 patients who died during the first 69 days after transplantation without platelet engraftment were censored. The median time to platelet engraftment was 13 days (range 7-52 days). A total of 212 patients (94.2%) received platelet transfusions (median ¼ 4 platelet packs or 20 units). Patients who received 43 Â 10 6 /kg CD34 þ stem cells had an earlier platelet recovery (median, 12 days; 25th and 75th percentiles, 11 and 15 days) than did patients who received a lower dose (median, 15 days; 25th and 75th percentiles, 12 and 20 days) ( Table 2) .
A Cox proportional hazard regression model showed that serum creatinine levels p1.2 mg/dl, proteinuria o5 g/ day, CD34 þ cell dose 43 Â 10 6 /kg, and the absence of neutropenic fever were associated with more rapid platelet engraftment in univariate and multivariate analyses (Tables 1 and 4, Figure 3 /kg CD34 þ cells, there were no differences in the rate of platelet engraftment with further increases in stem cell dose.
Renal function also influenced platelet engraftment. The degree of proteinuria was associated with significant delays in platelet engraftment. The greatest differences in this regard were observed when patients with o5 g/day proteinuria were compared with those with X5 g/day (HR ¼ 1.48, 95% CI ¼ 1.12-1.97, Po0.01). Patients with a normal serum creatinine level (p1.2 mg/dl) also achieved platelet engraftment more rapidly than did those with elevated creatinine levels (HR ¼ 1.58 95% CI ¼ 1.04-2.42, P ¼ 0.03). Finally, patients who did not have neutropenic fever had rates of platelet engraftment that were 1.35 times greater than those who did (95% CI 1.02-1.79, P ¼ 0.03).
RBC transfusions
A total of 167 patients (74.2%) required RBC transfusions (median ¼ four units). Multiple linear regression analysis showed that hemorrhagic complications, baseline serum creatinine level, and neutropenic fever were significant predictors of the need for RBC transfusions (adjusted R 2 ¼ 0.43, Po0.01) ( Table 5) . Patients who had grades 3-4 hemorrhagic complications received a mean of 9.3 more units of RBCs compared to patients without such complications (95% CI 7.69-10.87, Po0.01). There was also a positive association between RBC units transfused and baseline serum creatinine level and the presence of neutropenic fever. Overall, there was an average increase of 1.1 PRBC units administered to patients with each successive category of increased baseline serum creatinine (as described in the Methods; 95% CI 0.34-1.88, Po0.01). Finally, the average difference in mean number of PRBC transfusions between patients who had neutropenic fever vs those who did not was 1.42 (95% CI 0.33-2.52, P ¼ 0.01).
Discussion
The goal of this study was to determine predictive factors for hematopoietic engraftment in patients with AL amyloidosis after high-dose melphalan chemotherapy and PBSC transplantation (HDM/SCT). Owing to the potential impact of bone marrow infiltration with amyloid and varying degrees of organ dysfunction upon hematopoietic engraftment in this unique patient population, it was anticipated that the characteristics of engraftment might be different from those reported for other patient populations who undergo comparable treatment. In these patients, the median times to neutrophil and platelet engraftment were 10 and 13 days respectively, and CD34 þ stem cell dose was the strongest predictor of the timing of hematopoietic engraftment. These findings are similar to those reported in other transplantation studies that found CD34 þ cell dose to be the most significant variable associated with rapid recovery. 3, 4, 12, 13 Although some studies have found 2 Â 10 6 CD34 þ cells/kg to be the minimum threshold for successful engraftment, 14, 15 several studies have shown an association between a further increase in transplanted cell dose and the rate of engraftment. [16] [17] [18] [19] In our study, infusion of 43 Â 10 6 CD34 þ cells/ kg was found to provide more rapid platelet and neutrophil recovery, with delays of 3 and 1 days, respectively, at lower stem cell doses. For both end points, a stem cell dose exceeding 5 Â 10 6 CD34 þ cells/kg provided an additional benefit for engraftment (HR 1.40 and 1.70 for neutrophil and platelet engraftment, respectively), but no additional benefit was detected for even higher stem cell doses.
Although some studies have shown a reduction in RBC transfusion requirements with higher stem cell doses, 20, 21 we did not find this to be the case in our patient population. The lack of an association between stem cell dose and RBC transfusions may be due to a relatively higher incidence of grades 3-4 hemorrhagic complications in our study group (13.8%). The etiology of hemorrhagic complications in AL amyloidosis patients is multifactorial, and may involve vascular fragility from amyloid deposits and deficiency of factor X, in addition to thrombocytopenia.
Kidney is one of the most common sites of amyloid deposition in AL amyloidosis, with renal disease reported to occur in 48-82% of patients. [22] [23] [24] We have found that patients with renal failure, including those with end-stage renal disease on hemodialysis, can receive high-dose melphalan with no increase in peritransplant mortality, although the incidence and severity of mucositis and episodes of neutropenic fever are increased. 25 In a study of 81 multiple myeloma patients with renal failure, the median times to neutrophil and platelet engraftment were 11 and 41 days, respectively. 26 In a smaller study, platelet recovery was delayed in two of six such patients treated, and those two patients were still platelet transfusiondependent 10 and 28 months after transplantation. 27 We found that in AL amyloidosis patients with renal insufficiency and/or proteinuria X5 g/day, platelet engraftment, but not neutrophil engraftment, was delayed. The reason for this is unclear. One possible explanation could be impaired megakaryopoiesis in patients with renal involvement, perhaps due to a deficiency of thrombopoietin (TPO). The kidney is one source of TPO biosynthesis, and some studies have suggested that TPO levels are reduced 28 and megakaryocytopoiesis is defective 29 in patients on dialysis. To our knowledge, this is the first report demonstrating an association between nephrotic syndrome and delayed platelet engraftment.
Infection has been known to produce thrombocytopenia by shortening platelet lifespan. [30] [31] [32] We found that patients who had neutropenic fever had delayed platelet engraftment, with a median of 13 days compared to 12 days in those who did not experience fever while neutropenic. Direct damage to platelets by bacterial products, platelet adhesion to injured endothelium, platelet absorption of circulating immune complexes, and antiplatelet autoantibody production following transplant could contribute to increased platelet destruction. The small group of 11 patients who had clinical features consistent with sepsis had even greater delays in platelet engraftment, with a median of 18 days. Similar to platelet engraftment, we found that neutropenic fever and kidney failure were independent predictive factors for the number of RBC transfusions. The kidney is the major source of EPO, and EPO deficiency and anemia are well-recognized complications of renal failure. Moreover, infection has been shown to induce rheologic changes in erythrocytes and lead to as much as a 15% decline in RBC mass. 33 Among patients who did not have hemorrhagic complications, the only additional factor found to influence transfusion requirements was performance status of the patients at the time of treatment (data not shown). Interestingly, stem cell dose did not influence the RBC transfusion requirements.
Previous studies have shown that extensive prior exposure to alkylating agents is associated with significantly delayed platelet engraftment. 13, 34, 35 However, these studies did not find an association between prior cytotoxic therapy and delayed neutrophil engraftment. In the AL amyloidosis patients, we found the opposite, that is, delayed neutrophil engraftment but not delayed platelet engraftment, in those patients who had received 4100 mg of oral melphalan chemotherapy (equivalent to only about two cycles of standard cyclic melphalan and prednisone). A novel result from our analysis was the finding of an advantage for women with respect to rates of neutrophil engraftment, with a highly significant (Po0.01) hazard ratio of 1.51. The explanation for this is not known; typically androgens, not estrogens, have been thought to stimulate myelopoiesis. Our findings also include some important negative results. The dose of intravenous melphalan used for conditioning did not significantly affect the period of pancytopenia, although there was a trend towards slower engraftment with higher doses of chemotherapy. Although some patients with AL amyloidosis have extensive involvement of the bone marrow microvasculature and interstitium with amyloid fibrils, this did not appear to affect hematopoietic engraftment. Lastly, just as age has not been found to be a determinant of survival after HDM/SCT, 5 age was not found to influence the rapidity of hematopoietic engraftment, either in univariate or multivariate analyses. This further argues against denying dose-intensive therapy for AL amyloidosis to patients over 65 years who would otherwise be considered suitable for treatment.
In summary, our results suggest that, as for other diseases, CD34
þ stem cell dose has the greatest impact on hematopoietic engraftment in AL amyloidosis patients. Prior oral melphalan also affected engraftment independently of the stem cell dose, suggesting that prior exposure to oral chemotherapy may qualitatively alter the stem cells that are harvested and/or the bone marrow microenvironment. Thus, its use should be minimized in patients for whom autologous transplantation is planned. Renal disease retarded platelet, but not neutrophil, engraftment. While AL amyloidosis patients with renal involvement can be transplanted successfully, they may benefit from higher doses of autologous stem cells.
